AGY currently would not pass due diligence for a major miner's takeover. By the time we tick all the boxes, we'll have the re-rate derived from ML, offtake, sales, expansion underway, etc.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
